Logo image of PSNL

PERSONALIS INC (PSNL) Stock Fundamental Analysis

NASDAQ:PSNL - Nasdaq - US71535D1063 - Common Stock - Currency: USD

4.715  -0.71 (-13.17%)

After market: 4.75 +0.04 (+0.74%)

Fundamental Rating

2

Overall PSNL gets a fundamental rating of 2 out of 10. We evaluated PSNL against 56 industry peers in the Life Sciences Tools & Services industry. PSNL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PSNL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year PSNL has reported negative net income.
In the past year PSNL has reported a negative cash flow from operations.
In the past 5 years PSNL always reported negative net income.
PSNL had a negative operating cash flow in each of the past 5 years.
PSNL Yearly Net Income VS EBIT VS OCF VS FCFPSNL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

PSNL has a worse Return On Assets (-38.12%) than 78.95% of its industry peers.
PSNL has a Return On Equity of -54.83%. This is in the lower half of the industry: PSNL underperforms 68.42% of its industry peers.
Industry RankSector Rank
ROA -38.12%
ROE -54.83%
ROIC N/A
ROA(3y)-34.43%
ROA(5y)-27.22%
ROE(3y)-52.21%
ROE(5y)-40.27%
ROIC(3y)N/A
ROIC(5y)N/A
PSNL Yearly ROA, ROE, ROICPSNL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

PSNL's Gross Margin of 31.41% is on the low side compared to the rest of the industry. PSNL is outperformed by 70.18% of its industry peers.
In the last couple of years the Gross Margin of PSNL has declined.
PSNL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-4.55%
PSNL Yearly Profit, Operating, Gross MarginsPSNL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200 -250

4

2. Health

2.1 Basic Checks

PSNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PSNL has been increased compared to 1 year ago.
PSNL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PSNL has a worse debt to assets ratio.
PSNL Yearly Shares OutstandingPSNL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
PSNL Yearly Total Debt VS Total AssetsPSNL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.23, we must say that PSNL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.23, PSNL is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
PSNL has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PSNL's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. PSNL outperforms 75.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.23
ROIC/WACCN/A
WACC11.4%
PSNL Yearly LT Debt VS Equity VS FCFPSNL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

PSNL has a Current Ratio of 4.68. This indicates that PSNL is financially healthy and has no problem in meeting its short term obligations.
PSNL has a better Current ratio (4.68) than 68.42% of its industry peers.
A Quick Ratio of 4.44 indicates that PSNL has no problem at all paying its short term obligations.
PSNL has a Quick ratio of 4.44. This is in the better half of the industry: PSNL outperforms 71.93% of its industry peers.
Industry RankSector Rank
Current Ratio 4.68
Quick Ratio 4.44
PSNL Yearly Current Assets VS Current LiabilitesPSNL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.66% over the past year.
The Revenue has grown by 24.05% in the past year. This is a very strong growth!
PSNL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.24% yearly.
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)24.05%
Revenue growth 3Y-2.24%
Revenue growth 5Y14.24%
Sales Q2Q%40.89%

3.2 Future

The Earnings Per Share is expected to grow by 14.59% on average over the next years. This is quite good.
PSNL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.03% yearly.
EPS Next Y30.64%
EPS Next 2Y21.8%
EPS Next 3Y16.3%
EPS Next 5Y14.59%
Revenue Next Year13.84%
Revenue Next 2Y7.38%
Revenue Next 3Y14.38%
Revenue Next 5Y27.03%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PSNL Yearly Revenue VS EstimatesPSNL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
PSNL Yearly EPS VS EstimatesPSNL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2

0

4. Valuation

4.1 Price/Earnings Ratio

PSNL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSNL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSNL Price Earnings VS Forward Price EarningsPSNL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSNL Per share dataPSNL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PSNL's earnings are expected to grow with 16.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.8%
EPS Next 3Y16.3%

0

5. Dividend

5.1 Amount

PSNL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PERSONALIS INC

NASDAQ:PSNL (2/21/2025, 8:00:01 PM)

After market: 4.75 +0.04 (+0.74%)

4.715

-0.71 (-13.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners67.44%
Inst Owner Change-69.8%
Ins Owners1.06%
Ins Owner Change-0.32%
Market Cap399.31M
Analysts81.67
Price Target7.6 (61.19%)
Short Float %6.5%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.15%
Min EPS beat(2)-79.27%
Max EPS beat(2)36.97%
EPS beat(4)2
Avg EPS beat(4)-2.72%
Min EPS beat(4)-79.27%
Max EPS beat(4)37.32%
EPS beat(8)4
Avg EPS beat(8)0.35%
EPS beat(12)7
Avg EPS beat(12)2.11%
EPS beat(16)10
Avg EPS beat(16)3.16%
Revenue beat(2)2
Avg Revenue beat(2)16.56%
Min Revenue beat(2)14.93%
Max Revenue beat(2)18.2%
Revenue beat(4)3
Avg Revenue beat(4)8.77%
Min Revenue beat(4)-2.3%
Max Revenue beat(4)18.2%
Revenue beat(8)6
Avg Revenue beat(8)6.64%
Revenue beat(12)9
Avg Revenue beat(12)6.46%
Revenue beat(16)11
Avg Revenue beat(16)4.66%
PT rev (1m)-2.61%
PT rev (3m)5.67%
EPS NQ rev (1m)6.04%
EPS NQ rev (3m)10.94%
EPS NY rev (1m)0.23%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)1.33%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)1.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.56
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB 2.39
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS1.03
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.12%
ROE -54.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.41%
FCFM N/A
ROA(3y)-34.43%
ROA(5y)-27.22%
ROE(3y)-52.21%
ROE(5y)-40.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-4.55%
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.31%
Cap/Sales 4.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.68
Quick Ratio 4.44
Altman-Z 0.23
F-Score5
WACC11.4%
ROIC/WACCN/A
Cap/Depr(3y)290.96%
Cap/Depr(5y)221.15%
Cap/Sales(3y)34.84%
Cap/Sales(5y)24.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y30.64%
EPS Next 2Y21.8%
EPS Next 3Y16.3%
EPS Next 5Y14.59%
Revenue 1Y (TTM)24.05%
Revenue growth 3Y-2.24%
Revenue growth 5Y14.24%
Sales Q2Q%40.89%
Revenue Next Year13.84%
Revenue Next 2Y7.38%
Revenue Next 3Y14.38%
Revenue Next 5Y27.03%
EBIT growth 1Y35.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.66%
EBIT Next 3Y11.53%
EBIT Next 5YN/A
FCF growth 1Y51.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.15%
OCF growth 3YN/A
OCF growth 5YN/A